<Header>
<FileStats>
    <FileName>20161017_10-Q-A_edgar_data_1388410_0001388410-16-000049_1.txt</FileName>
    <GrossFileSize>39315</GrossFileSize>
    <NetFileSize>3314</NetFileSize>
    <ASCII_Embedded_Chars>21842</ASCII_Embedded_Chars>
    <HTML_Chars>10837</HTML_Chars>
    <XBRL_Chars>0</XBRL_Chars>
    <XML_Chars>0</XML_Chars>
    <N_Tables>1</N_Tables>
    <N_Exhibits>0</N_Exhibits>
</FileStats>
<SEC-Header>
0001388410-16-000049.hdr.sgml : 20161017
<ACCEPTANCE-DATETIME>20161014210744
ACCESSION NUMBER:		0001388410-16-000049
CONFORMED SUBMISSION TYPE:	10-Q/A
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20150930
FILED AS OF DATE:		20161017
DATE AS OF CHANGE:		20161014

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PARALLAX HEALTH SCIENCES, INC.
		CENTRAL INDEX KEY:			0001388410
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]
		IRS NUMBER:				721619357
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52534
		FILM NUMBER:		161937860

	BUSINESS ADDRESS:	
		STREET 1:		1327 OCEAN AVENUE, SUITE M
		CITY:			SANTA MONICA
		STATE:			CA
		ZIP:			90401
		BUSINESS PHONE:		310-899-4442

	MAIL ADDRESS:	
		STREET 1:		1327 OCEAN AVENUE, SUITE M
		CITY:			SANTA MONICA
		STATE:			CA
		ZIP:			90401

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ENDEAVOR POWER CORP.
		DATE OF NAME CHANGE:	20140110

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Endeavor Power Corp
		DATE OF NAME CHANGE:	20090105

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Endeavor Uranium, Inc.
		DATE OF NAME CHANGE:	20071113

</SEC-Header>
</Header>

 0001388410-16-000049.txt : 20161017

10-Q/A
 1
 f20150930prlxform10qa.htm
 QUARTERLY REPORT-AMENDMENT

Quarterly Report 

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
  Washington, D.C. 20549       
  Form 10-Q/A   
 (Mark One)  
  x   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   
 For the quarterly period ended   September 30, 2015   
 
 or  
        TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  
 
  For the transition period from__________ to _________  
 
Commission File Number     000-52534    
   
   PARALLAX HEALTH SCIENCES, INC.  
   (  Exact name of registrant as specified in its charter)   

Copy of all Communications to : 
 Lawrence I. Washor 
 Washor   Associates 
 21800 Oxnard Street, Suite 790 
 Woodland Hills, CA 91367 
 (310) 479-2660 
   
 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  

YES        x   NO   
 Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). 
  x   YES                NO  
 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company. See the definitions of    large accelerated filer   ,    accelerated filer    and    smaller reporting company    in Rule 12b-2 of the Exchange Act. 

Large accelerated filer 
       
        Accelerated filer 

Non-accelerated filer 
       
        Smaller reporting company 
     x   
  
   (Do not check if a smaller reporting company) 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) 
        YES        x   NO   
   
  APPLICABLE ONLY TO CORPORATE ISSUERS   
   
 Indicate the number of shares outstanding of each of the issuer   s classes of common stock, as of the latest practicable date. 
   
  105,566,774 common shares issued and outstanding as of September 30, 2016  

EXPLANATORY NOTE  

This Amendment No. 1 to the Quarterly Report on Form 10-Q/A is being filed solely to correct the number of shares outstanding as of the last practicable date, above. No other changes have been made to the Form 10-Q, as originally filed on October 13, 2016. 

SIGNATURES  
 Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.  

PARALLAX HEALTH SCIENCES, INC.  

Dated: October 14, 2016 
    /s/ J. Michael Redmond  
  
         J. Michael Redmond  

President, Chief Executive Officer and Director  

Dated: October 14, 2016 
    /s/ Calli Bucci  
  
         Calli Bucci  

Chief Financial Officer  

